Fresenius Kabi receives European Commission approval for adalimumab biosimilar Idacio

Fresenius Kabi

3 April 2019 - The European Commission granted Fresenius Kabi the marketing authorization for Idacio, an adalimumab biosimilar, for all indications of the reference medicine. 

With this approval, Idacio is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

Read Fresenius press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Biosimilar